This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?

Th the past year otal revenue came in at $34.1 billion, 20% higher than the previous fiscal year.

Some analysts expect 1 he medic Eli Lilly t peak annual revenue of $25 billion.

The Stock Advisor service has more t Mounjaro led the return of S&P 500 sin Zepbound .

Stock Advisor returns as Eli Lilly ry 5, 2024 This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy? was originally published by The Motley Fool. The Motley Fool This annual pable Growth $25 billion A Humira ed< yearly just $21.2 billion hLightText__NxlGi">February 5, 2024 2002 each month two the coming years 10 nonalcoholic _NxlGi">one Eli Lilly 10 The Motley Fool Stock Advisor Eli Lilly< the coming years ass="summar first _highLightText__NxlGi">Eli Lilly the U.S. Food and Drug Administration hLightText__NxlGi">1 this year n> Eli Lilly Eli Lilly htText__NxlGi">th fourth-quarter 2 LightTex 74% NxlGi">Eli Lilly 15 pan class="summaryFeed_highLightText__NxlGi">2 week 52 class="summaryFeed_highLightText__NxlGi">the Only about 13% s this year Tirzepatide summaryFeed_highLightText__NxlGi">2023 2022 3 bout $2 billion COVID-19 Eli Lilly's __NxlGi">last year Eli Lilly Last year >S Mounjaro pan> FDA $5.2 billion "summaryFeed_highLightText__NxlG first unjaro May of 2022 ss="summaryFeed_highLightText__NxlGi">late $5 billion /span> $482.5 million > 2022 hLightText__NxlGi">First Eli Lilly's aryFeed_highLight last year Gi">20% $34.1 billion __ 20% Gi">this year the previous fiscal year mmaryFeed_highLightText__NxlGi">Lilly